Veravas is a laboratory diagnostic company specializing in early detection of disease-related biomarkers. They have developed a breakthrough patient sample transformation technology called Vera BIND (Biomarker Isolation and N-richment for Detection). This technology can purify and concentrate biomarkers of interest from complex sample types such as saliva, blood, urine, and stool, creating a new matrix-free sample.

The detection of biomarkers free from the sample matrix allows for the development of highly accurate assays using any detection methodology. Veravas' products are designed with convenience, sensitivity, accuracy, and cost-effectiveness in mind. They cater to researchers, lab directors, commercial test manufacturers, and even themselves, providing highly sensitive assays for early disease detection, clinical trials, precision diagnosis, and treatment monitoring.

Veravas is currently working on the development of saline oral rinse tests for diseases such as Alzheimer's, Lyme, and Celiac disease. For more information, visit their website at veravas. com or follow them on social media channels: Facebook, Twitter, and LinkedIn